ClinicalTrials.gg
RecruitingNCT07567872Updated Jul 20, 2026

A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-9821 Powder for Inhalation Administered as a Single Dose in Healthy Participants and Multiple Doses in Patients With COPD

A Phase 1 interventional study of HRS-9821 Powder for Inhalation and Placebo in COPD, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-20.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China — 108 open to participants now, 125 under way, 15 of them phase 3. Pulmonary Disease, Chronic Obstructive · China.

Planned enrollment
214th of 286
48 · median 155
Started
2026
with 33 others
Phase 1
28 of 404
4 open now
Primary completion
2026-09
later than 42 of 124 live
Registered
381st of 404
by date

Among the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, this one is the 214th largest by planned enrollment of the 286 interventional ones that give a count, is one of 34 that started in 2026, is one of 28 in phase 1, reaches primary completion later than 42 of the 124 other live ones, and was the 381st registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

108 of the 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China are open now. Recruiting first, the newest first:

102 more — sign in →

All 108 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 404 studies in Pulmonary Disease, Chronic Obstructive with a site in China, or all of them as a file.
02

Study summary

The aim of this study was to evaluate the safety and tolerability of HRS-9821 Powder for Inhalation administered in a single dose in healthy individuals and multiple doses in patients with COPD。

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. was obtained to participate in the trial
  2. Body weight ≥45 kg,and 18-33 kg/m2 (both ends included)
  3. The 12-lead was normal or abnormal but clinically insignificant until randomization
  4. was strict from the time informed consent was signed until 1 month (for subjects receiving HRS-9821/ placebo) or 3 months (for male subjects receiving moxifloxacin) after the last dose
  5. All study regulations and procedures were followed and inhalation devices used in the study were used correctly during the study

    The following inclusion criteria apply only to healthy subjects:

  6. Vital signs were normal at screening
  7. Pulmonary function was normal during screening
  8. No smoking or smoking cessation ≥12 months before screening, and previous smoking history \<5 pack-years;
  9. Healthy male 18-50 years old

    The following inclusion criteria apply only to subjects with

  10. Male or female, aged 40-75 years;
  11. Patients diagnosed with COPD;
  12. A post-bronchodilator /FVC \< 0.7,40% ≤FEV1 \< 80% of the predicted value,;
  13. Smoking history of≥ 10 pack-years;
  14. Normal chest X-ray examination results at screening;
  15. Supporting discontinuation of COPD-related medications before randomization;

Exclusion criteria

Exclusion Criteria:

  1. Mean ≥ 450 ms at screening;
  2. Persons who had donated blood or had massive blood loss (> 400 ml) within 4 weeks before screening or who were interested in donating blood during the study
  3. Receipt of the drug or device within 4 weeks before randomization or less than 5 times the half-life of the drug, whichever was greater;
  4. Patients who had difficulty in blood collection or could not tolerate venipuncture in the past, such as dizzy with needles or blood
  5. History of in any organ system
  6. Known allergies to salbutamol, study medication, or any in the formulation
  7. Known previous infection with (HIV), virus (HBV) or virus (HCV); Or positive HIV (according to a trial-site SOP), treponema pallidum antibody, HBV surface antigen, or HCV antibody before randomization
  8. History of alcohol abuse
  9. History of drug abuse and drug dependence in the past 5 years;
  10. Positive for alcohol or substance abuse test before randomization
  11. During the study, surgery or treatment that might interfere with the conduct of the study was planned;
  12. Unable or unwilling to fully adhere to the study protocol
  13. Mentally or legally incapacitated
  14. There were any other reasons for the subject not to participate in the study in the opinion of the investigator;
  15. Use of a strong/moderate potency drug that inhibits or induces the hepatic drug-metabolizing enzyme 14 days before the first dose;
  16. Drugs with effects on P-glycoprotein (P-gp) or breast cancer resistance protein (BCRP) were anticipated to be used during the study;
  17. History of using HRS-9821 suspension;

    The following exclusion criteria apply only to healthy subjects:

  18. Have been treated with antibiotics for upper and lower respiratory tract infections within 12 weeks prior to screening;
  19. Abnormal laboratory or physical examination results with clinical significance;
  20. Positive urine nicotine test before randomization;
  21. Have consumed a prescription within 14 days prior to the first dose or over-the-counter drugs within 48 h prior to the first dose;

The following exclusion criteria apply only to subjects with 22. History of life-threatening acute exacerbation of COPD (AECOPD), including admission to intensive care unit and/or need for invasive ventilator support; 23. Diagnosed with other respiratory disorders; 24. Pulmonary heart disease, or pulmonary hypertension caused by lung disease and/or hypoxia; 25. History of lung volume reduction surgery, partial lung resection, lung transplantation, and other surgeries that may affect pulmonary function results; 26. History of AECOPD requiring systemic or antibiotics or hospitalization within 4 weeks prior to screening; 27. Lower respiratory tract infection requiring antibiotic treatment within 4 weeks prior to screening; 28. Requiring oxygen therapy or home non-invasive ventilation; 29. Currently using or plan to use non-selective beta blockers or other drugs with bronchoconstrictive effects during the study; 30. Patients with serious trauma or major surgery within 6 months prior to screening who are still in the recovery period; 31. Abnormal laboratory tests at screening and baseline.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    HRS-9821 Powder for Inhalation

    Participants inhaled HRS-9821 powder either as a single dose or for 12 days.

    Drug: HRS-9821 Powder for Inhalation

  • Placebo comparator
    placebo for HRS-9821 Powder Inhalation

    Participants received a single dose or 12 consecutive days of placebo for HRS-9821 Powder Inhalation with HRS-9821.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in the rate of adverse events

    Time frame: The screening period lasted until 26days after administration

Secondary outcomes

  1. Plasma drug concentration after administration

    Time frame: The screening period lasted until 21 days after administration

07

Study locations

1 of 1 sites recruiting
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610044, China
    Recruiting
    • Zhu Luo · Principal investigator
    • Wei min Li · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Sep 2026, 2 months after the start.

Of 158 industry-sponsored phase 1 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 4 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 9. This study's planned 2 months is below that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 2 and three quarters within 11.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 5, 2026
StartActual
Jul 9, 2026
Primary completionEst.
Sep 2026
CompletionEst.
Sep 2026
Last update
Jul 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07567872
Responsible party
Sponsor
First posted
May 5, 2026
Start date
Jul 9, 2026
Primary completion
Sep 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
Jul 20, 2026

Study contacts

Liping Liu
Contact
Liping.liu.ll5@hengrui.com
+86 18217192573

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-9821

Start the discussion